NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis → why 99.94% won’t make you money (From Prosper Trading Academy) (Ad) Free MAIA Stock Alerts $3.76 -0.02 (-0.53%) (As of 11:35 AM ET) Add Compare Share Share Today's Range$3.65▼$3.9250-Day Range N/A52-Week Range$0.82▼$5.99Volume50,455 shsAverage Volume414,146 shsMarket Capitalization$82.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get MAIA Biotechnology alerts: Email Address Ad Behind the MarketsProtect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.Discover these 4 simple steps here >>> About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA)MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Read More MAIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAIA Stock News HeadlinesJune 7, 2024 | businesswire.comMAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent TherapyJune 6, 2024 | businesswire.comMAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer AgentJune 18, 2024 | Prosper Trading Academy (Ad)why 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.June 4, 2024 | businesswire.comMAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung CancerMay 17, 2024 | businesswire.comMAIA Biotechnology to Present at the BIO International Convention 2024May 16, 2024 | businesswire.comMAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingMay 15, 2024 | investorplace.comMAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024April 30, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementJune 18, 2024 | Prosper Trading Academy (Ad)why 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.April 29, 2024 | marketwatch.comMAIA Biotechnology Shares Hit 52-Week High After Director Stock PurchaseApril 29, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private PlacementApril 28, 2024 | finance.yahoo.comMAIA Biotechnology, Inc. (MAIA)April 23, 2024 | businesswire.comMAIA Biotechnology Announces $1.00 Million Private PlacementApril 5, 2024 | businesswire.comMAIA Biotechnology to Present at Two Investor Conferences in April 2024April 4, 2024 | msn.comeFFECTOR shelves tomivosertib in NSCLC following Phase II failureMarch 28, 2024 | investing.comMAIA Biotechnology directors buy shares amid development pushMarch 28, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro GuerreroMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces $1.33 Million Private PlacementMarch 22, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private PlacementMarch 21, 2024 | businesswire.comMAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory BoardMarch 16, 2024 | finance.yahoo.comDirector Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)March 14, 2024 | msn.comMAIA Biotechnology rises 3% on $2.92M private placementMarch 7, 2024 | finance.yahoo.comMAIA Biotechnology to Participate in the 36th Annual ROTH ConferenceMarch 7, 2024 | investing.comMAIA Biotechnology nears end of Phase 2 cancer trialMarch 6, 2024 | markets.businessinsider.comMAIA Announces Positive Data From Phase 2 THIO Clinical Trial For NSCLC; Stock Rises 8%March 6, 2024 | finance.yahoo.comMAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingSee More Headlines Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:MAIA CUSIPN/A CIKN/A Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,189.07% Return on Assets-282.82% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book127.00Miscellaneous Outstanding Shares21,840,000Free Float13,762,000Market Cap$83.21 million OptionableNot Optionable Beta0.45 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Vlad Vitoc M.B.A. (Age 54)M.D., Co-Founder, President, CEO & Chairman of the Board of Directors Comp: $529.82kMr. Jeffrey C. Himmelreich (Age 49)Head of Finance Comp: $213.17kDr. Sergei M. Gryaznov Ph.D. (Age 64)Chief Scientific Officer Comp: $417.33kLinda MoreiraCompany SecretaryKey CompetitorsXeris BiopharmaNASDAQ:XERSEmergent BioSolutionsNYSE:EBSAtea PharmaceuticalsNASDAQ:AVIRAlto NeuroscienceNYSE:ANROSilverback TherapeuticsNASDAQ:SBTXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 32,487 shares on 5/20/2024Ownership: 0.149%Ngar Yee LouieBought 19,665 shares on 4/25/2024Total: $39,919.95 ($2.03/share)Stan SmithBought 170,940 shares on 3/14/2024Total: $199,999.80 ($1.17/share)View All Insider TransactionsView All Institutional Transactions MAIA Stock Analysis - Frequently Asked Questions Are investors shorting MAIA Biotechnology? MAIA Biotechnology saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 623,700 shares, a decrease of 48.9% from the May 15th total of 1,220,000 shares. Based on an average trading volume of 447,600 shares, the short-interest ratio is presently 1.4 days. Approximately 3.6% of the shares of the company are short sold. View MAIA Biotechnology's Short Interest. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.13. Who are MAIA Biotechnology's major shareholders? MAIA Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.15%). Insiders that own company stock include Cristian Luput, Joseph F Mcguire, Ngar Yee Louie, Ramiro Guerrero, Stan Smith and Vlad Vitoc. View institutional ownership trends. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MAIA) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
